Filing Flows › Mirum Pharmaceuticals (MIRM) › Q2 2026 › vs Q1 2026
Mirum Pharmaceuticals (MIRM) Q2 2026 vs Q1 2026 (quarter over quarter)
Mirum Pharmaceuticals's revenue rose $16.4M (+10%) from $160M in Q1 2026 to $176M in Q2 2026. The biggest changes: Livmarli +$14.9M (+13%); Bile Acid Medicines +$1.4M (+3%).
Mirum Pharmaceuticals, Q2 2026: revenue $176M (+38% year over year), operating margin -24.1%, net loss $67.2M, operating cash flow −$44.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Livmarli | $129M | $114M | $14.9M | +13% |
| Bile Acid Medicines | $47.5M | $46.1M | $1.4M | +3% |
| Revenue | $176M | $160M | $16.4M | +10% |
| Net loss | $67.2M | $790M | −$723M | -91% |
| Costs & expenses | $243M | $950M | −$707M | -74% |
| Operating costs | $219M | $949M | −$731M | -77% |
| Interest & other, net | $23.0M | $215K | $22.8M | 107× |
| Income tax | $1.7M | $475K | $1.2M | +256% |
| Research & development | $90.5M | $97.9M | −$7.4M | -8% |
| SG&A | $81.5M | $96.3M | −$14.9M | -15% |
| Other operating costs | $46.8M | $755M | −$708M | -94% |
| Operating cash sources | $81.8M | $272M | −$190M | -70% |
| Depreciation & amortization | $6.9M | $6.9M | $62K | +0.9% |
| Share-based compensation | $30.6M | $36.2M | −$5.6M | -16% |
| Cash used in operations | $44.3M | $229M | −$185M | -81% |
| Net loss absorbed | $67.2M | $790M | −$723M | -91% |
| Working capital & other | $14.5M | −$518M | $533M | — |
Questions
How much did Mirum Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Mirum Pharmaceuticals's revenue rose $16.4M (+10%) from $160M in Q1 2026 to $176M in Q2 2026.
What drove Mirum Pharmaceuticals's revenue change in Q2 2026?
Livmarli +$14.9M (+13%); Bile Acid Medicines +$1.4M (+3%).